Protagonist Therapeutics (PTGX) Net Equity Issued and Repurchased (2016 - 2023)

Protagonist Therapeutics (PTGX) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $8000.0 in Q4 2023.

• For the quarter ending Q4 2023, Net Equity Issued and Repurchased fell 82.98% year-over-year to $8000.0; the trailing twelve-month figure through Dec 2023 stood at $24.3 million (down 77.39% YoY), and the FY2023 full-year result was $107.8 million, up 638.34% from the prior year.
• Net Equity Issued and Repurchased grew to $8000.0 in Q4 2023, from -$78000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $107.6 million in Q4 2020 to a low of -$19.9 million in Q4 2019.
• A 5-year average of $14.1 million and a median of $3.2 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased plunged 4289.47% in 2019 and jumped 640.7% in 2020, its largest moves.
• Tracing PTGX's Net Equity Issued and Repurchased over 5 years: stood at -$19.9 million in 2019, then jumped by 640.7% to $107.6 million in 2020, then plunged by 100.15% to -$166000.0 in 2021, then surged by 128.31% to $47000.0 in 2022, then slumped by 82.98% to $8000.0 in 2023.
• Business Quant data shows PTGX's Net Equity Issued and Repurchased at $8000.0 in Q4 2023, -$78000.0 in Q3 2023, and $68000.0 in Q2 2023.